Anti-VEGF antibody [5C3.F8] (ab3109)

Overview

• Product nameAnti-VEGF antibody [5C3.F8]See all VEGF primary antibodies ...
• Description
  Mouse monoclonal [5C3.F8] to VEGF
• Tested applicationsICC/IF, IHC-P, WB more details
• Species reactivity
  Reacts with: Mouse, Human
  
• Immunogen

  Human VEGF from a glioma.

• Positive controlWB: human VEGF 165 recombinant protein IHC-P: mouse islet grafts This antibody gave a positive result in IF in the following Methanol fixed cell line: HepG2.

Properties

• FormLiquid
• Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
• Storage buffer10mM PBS, pH7.4, 0.2%BSA, 0.09% sodium azide
• Concentration information loading...
• PurityProtein G purified
• Clonality Monoclonal
• Clone number5C3.F8
• IsotypeIgG1
• Light chain typekappa
• Research Areas
  • Metabolism
  • Pathways and Processes
  • Metabolism processes
  • Hypoxia

  • Metabolism
  • Types of disease
  • Cancer

  • Metabolism
  • Pathways and Processes
  • Cofactors, Vitamins / minerals
  • Co-factors

  • Developmental Biology
  • Organogenesis
  • Angiogenesis and vasculogenesis

  • Cancer
  • Growth factors
  • VEGF

  • Cancer
  • Cancer Metabolism
  • Response to hypoxia

  • Cancer
  • Invasion/microenvironment
  • Angiogenesis
  • Angiogenic growth factors

  • Signal Transduction
  • Growth Factors/Hormones
  • VEGF

  • Cardiovascular
  • Angiogenesis
  • Growth Factors
  • VEGF
  • VEGF

Applications

Target

• FunctionGrowth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.
• Tissue specificityIsoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed.
• Involvement in diseaseDefects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:603933]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
• Sequence similaritiesBelongs to the PDGF/VEGF growth factor family.
• Cellular localizationSecreted. VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a signicant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.

Target information above from: UniProt accession P15692 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010) .

Information by UniProt
• Database links
  • Entrez Gene: 7422 Human
  • Entrez Gene: 22339 Mouse
  • Omim: 192240 Human
  • SwissProt: P15692 Human
  • SwissProt: Q00731 Mouse
  • Unigene: 73793 Human
  • Unigene: 282184 Mouse

• Alternative names
  MGC70609 antibodyVascular endothelial growth factor A antibodyVascular Endothelial Growth Factor antibody

  Vascular Permeability Factor antibodyVEGF-A antibodyVEGFA antibodyVEGFA_HUMAN antibodyVPF antibody

  see all

Anti-VEGF antibody [5C3.F8] images

• 

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - VEGF antibody [5C3.F8] (ab3109)Copyright American Diabetes Association from Diabetes Vol 53, 2004:963-970. Reprinted with permission from the American Diabetes Association
  ab3109 staining VEGF in mouse islet grafts by Immunohistochemistry (FFPE-sections).
• 

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - VEGF antibody [5C3.F8] (ab3109)Copyright American Diabetes Association from Diabetes Vol. 53, 2004:963-970. Reprinted with permission from the American Diabetes Association
  ab3109 staining VEGF in mouse islet grafts by Immunohistochemistry (FFPE-sections).
• 

  Immunocytochemistry/ Immunofluorescence - Anti-VEGF antibody [5C3.F8] (ab3109)

  ab3109 stained HepG2 cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody ab3109 at 10µg/ml overnight at +4°C. The secondary antibody (green) was DyLight® 488 goat anti- mouse (ab96879) IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.